Category Archives: Biotechnology

Bromisoval Market report provides substantial information on the industry size, share, trends and applications; further offering vital statistics to market players and investors. Such information poses a high level accuracy as the data is sourced from reliable entities and figures denoted are summed after extensive market analysis. The data obtained from the report eases the process of predicting upcoming market opportunities.

Encompassing a comprehensive overview on market size, share and growth opportunities, Bromisoval market report allows to gather detailed insights on segmental growth which is propelled by specific applications in the key regions and countries as per denoted in the table of content. For this, the report considers market volumes and numbers generated from the segmental analysis.

Such segmentation uncovers various hidden trends and market statistics that may highly influence the decisions of various participants, including investors and new market entrants. The report also presents detailed analysis of the major vendors and manufacturers in the market further proving helpful to the start-ups looking to set up their business portfolios in the Bromisoval market.

Avail PDF Sample Pages of Bromisoval Market Report here @ https://www.acquiremarketresearch.com/sample-request/302582/

The Various segmentation of the market based on various factors:

Market Players:

Sumitomo Seika, CR Double-Crane, Haitian Biotechnology, Huashang Pharmaceutical

By Type:

Purity Above 98%, Purity Below 98%

By Application:

Bromisoval Tablet, Bromisoval Injection, Other

The Key regions are extensively analyzed with respect to every parameter of the geographies in question, comprising, North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.)

Inquire for further detailed information of Bromisoval Market Report @https://www.acquiremarketresearch.com/enquire-before/302582/

From the Bromisoval market research reports, the following points are available with detailed study at every point:

Production Analysis Initiation of this Bromisoval is analyzed relying on top countries, types, and applications. Here, the report will extensively cover price analysis of varied Bromisoval market key players.

Profit and Sales Evaluation Both earnings and sales are verified for various components of this international Bromisoval market. Still another crucial aspect, the price that plays a vital role in sales development can be assessed in this section for several regions.

Segments and Advantages In continuation of using earnings, this report studies design and ingestion to its Bromisoval market. This report also highlights the difference between usage and supply, export, and import data.

Competition In this section, many global Bromisoval industry-top players have been studied depending on their company profile, product portfolio, ability, price, cost, and revenue.

Other Analysis Aside from the above information, demand, and supply scrutiny to the Bromisoval economy, contact information from leading producers, suppliers, and major consumers can also be allocated.

Finally : It comprehensively evaluates the global Bromisoval market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional market growth, key players operating analysis, market segmentation, and other many of the important aspects.

To get full access of report @ https://www.acquiremarketresearch.com/industry-reports/bromisoval-market/302582/

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

See the original post:
Know the Future Opportunities of Bromisoval Market and its detail analysis by Focusing Top Companies like Sumitomo Seika, CR Double-Crane, Haitian...

New Jersey, United States, Verified Market Research offers its latest report on the Nanoparticles in Biotechnology and Pharmaceuticals Market that includes a comprehensive analysis of a range of subjects such as market growth status, competition, segmentation, regional expansion, and market dynamics. The report includes an exhaustive analysis of the overall industry size and structure based on primary and secondary research, fieldwork, and expertise. The report also sheds light on market future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Nanoparticles in Biotechnology and Pharmaceuticals market. Get access to crucial market information.

The researchers have studied the key development activities and tactics of the leading Nanoparticles in Biotechnology and Pharmaceuticals vendors including partnerships, acquisitions, mergers, technological development, research and development activities, and portfolio expansion. Besides, the report offers recommendations for the companies to sustain their hold in the marketplace.

Top 10 Companies in the Nanoparticles in Biotechnology and Pharmaceuticals Market Research Report:

The research study has segregated the Nanoparticles in Biotechnology and Pharmaceuticals industry into segments, including product type, application, and vertical, to broaden the overall understanding of the industry. This assessment has been carried out on the basis of size, share, and CAGR. Additionally, regional analysis has been done by the experts stressing the growth potential of the key regions and countries. The report also encompasses accurate and reliable figures based on Nanoparticles in Biotechnology and Pharmaceuticals consumption and production in key regions.

North America (United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

The Middle East and Africa (GCC Countries and Egypt)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=OMR&utm_medium=002

What the Report has in Store for you?

Industry Size & Forecast: The industry analysts have offered historical, current, and estimated projections of the industry size from the value and volume point of view

Future Opportunities: In this section of the report, Nanoparticles in Biotechnology and Pharmaceuticals participants are provided with the information on the future prospects that the Nanoparticles in Biotechnology and Pharmaceuticals industry is likely to offer

Industry Trends & Developments: Here, authors of the report have talked about the major trends and developments taking place in the Nanoparticles in Biotechnology and Pharmaceuticals marketplace and their estimated impact on the overall growth

Study on Industry Segmentation: Detailed breakdown of the key Nanoparticles in Biotechnology and Pharmaceuticals industry segments including product type, application, and vertical has been done in this portion of the report

Regional Analysis: Nanoparticles in Biotechnology and Pharmaceuticals vendors are offered crucial information of the high growth regions and their respective countries, thus helping them to invest in profitable regions

Competitive Landscape: This unit of the report throws light on the competitive scenario of the Nanoparticles in Biotechnology and Pharmaceuticals industry by focusing on the key strategies taken up by the vendors to consolidate their presence in the Nanoparticles in Biotechnology and Pharmaceuticals business.

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=OMR&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market

Read more:
Nanoparticles in Biotechnology and Pharmaceuticals Market Overview, Top Companies, Region, Application and Forecast by 2026 Oxon Market Reports -...

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) just released its yearly report and things are looking bullish. Results overall were solid, with revenues arriving 9.7% better than analyst forecasts at 40m. Higher revenues also resulted in substantially lower statutory losses which, at 0.58 per share, were 9.7% smaller than analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what analysts' statutory forecasts suggest is in store for next year.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

XTRA:BNN Past and Future Earnings, January 18th 2020

Following the latest results, B.R.A.I.N. Biotechnology Research and Information Network's four analysts are now forecasting revenues of 43.5m in 2020. This would be a solid 8.6% improvement in sales compared to the last 12 months. Per-share statutory losses are expected to see a sharp uptick, reaching 0.47. Before this earnings announcement, analysts had been forecasting revenues of 40.0m and losses of 0.29 per share in 2020. While next year's revenue estimates increased, there was also a large cut to EPS expectations, suggesting the consensus has a bit of a mixed view of these results.

There was no major change to the consensus price target of 17.80, with growing revenues seemingly enough to offset the concern of growing losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on B.R.A.I.N. Biotechnology Research and Information Network, with the most bullish analyst valuing it at 24.00 and the most bearish at 9.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Zooming out to look at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up both against past performance, and against industry growth estimates. We would highlight that B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, with forecast 8.6% increase next year well below the historical 15%p.a. growth over the last five years. By way of comparison, other companies in this market with analyst coverage, are forecast to grow their revenue at 3.8% next year. So it's pretty clear that, while B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, it's still expected to grow faster than the market itself.

Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider market. The consensus price target held steady at 17.80, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for B.R.A.I.N. Biotechnology Research and Information Network going out to 2024, and you can see them free on our platform here.

Story continues

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Go here to read the rest:
BRAIN Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Solomon Page, a leading global executive search firm servicing the Healthcare and Life Sciences industries, drives expansion through the hire of industry expert Luigi Frezza, who was named Managing Director, Life Sciences. Reporting into President & Global Practice Leader Marc Gouran, Frezza will be based in the London office and drive the growth of the Life Sciences team globally; partnering with companies in the Pharmaceutical, Biotech, Medical Devices and Diagnostics sectors.

Based in Manhattan, NY and with office locations throughout the U.S. and Europe, Solomon Page will continue to serve as a global partner in healthcare and life sciences executive search, while simultaneously expanding the company's footprint into new markets. "Our legacy of success spans across every branch of the Healthcare industry," Gouran said. "With Luigi now leading our Life Sciences practice based in London, we will continue to grow our global network by providing premiere consultative services and best-in-class solutions to both longstanding partners and new clients."

In support of this expansion, additional hires include Vice President Kristen Dorn and Consultant Shanon Yeow, who are both based in the recently opened Conshohocken, Pa. office.

Before joining Solomon Page, Frezza led the Pharmaceutical and Biotech practice of a medium-sized, boutique executive search firm across Europe and the U.S. With over 15 years of experience in the industry, including time spent at Korn Ferry, Frezza has an extensive background in working on search mandates across multiple functions, with a focus on senior roles in R&D, Technical and Commercial Operations, General Management as well as a broad range of corporate functional roles. "I am thrilled to be joining Marc and his team to support the growth of Solomon Page Healthcare & Life Sciences business on an international level," said Frezza. "In conjunction with Shanon and Kristen's efforts, the expansion of our Life Sciences division will round-out our full scope of services within the Healthcare sector. We look forward to making an impact on the industry by providing our clients, who trust us for our knowledge and experience, with valuable insight and unprecedented results."

About Solomon Page Founded in 1990, Solomon Page is a specialty niche provider of recruitment and executive search solutions across a wide array of functions and industries. The success of Solomon Page reflects an organic growth strategy supported by a highly entrepreneurial culture. Acting as a strategic partner to clients and candidates, Solomon Page focuses on providing customized solutions and building long-term relationships based on trust, respect, and the consistent delivery of excellent results. For additional information, visit solomonpage.com.

SOURCE Solomon Page

View original post here:
Solomon Page Healthcare & Life Sciences Division Expands its Global Footprint within the Pharmaceutical, Biotechnology, Medical Device and...

As per the research conducted by Fast. MR, the report titled Seasonings & Spices Market By Product (Herbs, Salt & Salt substitutes, Spices), By Application (Bakery & Confectionery, Soup, Meat & Seafood, Sauce, Salad, & Dressing, Savory Snack, Other Applications), By Distribution Channel (Online Channels and Offline Channels) & Global Region Market Size, Trends, Opportunity, Forecast 2018-2024 provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Seasonings and Spices Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.

Spices and seasonings are generally used for food flavouring. Spices and seasonings are different from each other, Spices are plant substances you put on food to add flavour and extend the foods life, whereas seasonings include almost every substance added to a meal to enhance its flavour. The globalseasonings & spices marketreached a market valuation of USD XX.X Billion in 2018 and is estimated to grow at a CAGR of XX.X% during the forecast period, i.e., 2019-2024.

Get Latest Sample for Seasonings and Spices Market @https://www.fastmr.com/request-s/79

Market Insights

Growth Drivers Seasonings & spices Market

The Rise of Food Tourism

Food is one of the essential elements of the tourist experience. Billions of tourists are travelling around the world searching for new and special cuisines. Considering this rise in food tourism, the number of restaurants offering foreign cuisines across the globe. Also, tourists are not just eating new cuisines but are also willing to acquire recipe and ingredients to cook those dishes at home. The rise in food tourism have increased the demand for foreign cuisines such as Indian, Japanese, Chinese cuisines across the globe. The market for seasonings and spices are strongly driven by rising food tourism and has resulted in an increase in export and import of spices and seasonings around the world.

Raising Awareness of Health Benefits of Consuming Spices

Spices are nutritionally rich and offer numerous health benefits. Consumers around the world are willing to add these spices into their daily meals to stay healthy and fit. This rise in awareness has made food & beverage companies to incorporating spices into ready-to-eat and ready-to-drink foods and beverages. Apart from this, the market for fast food is also booming, increasing number of fast food outlets, rising disposable income and rapid urbanization across the globe are anticipated to foster the growth of global seasoning and spices market in upcoming years.

Barriers Seasonings & spices Market

Spices and seasonings market in most part the world is highly unorganized. This has adversely affected the growth and profitability of organized players. Presence of a large number of local players across the globe, especially in Asian countries is poised to hamper the growth of the market in the near future.

Market Trends Seasonings & Spices Market

Online Sales of Seasonings and Spices

The manufactures of seasonings & spices are strongly considering online channels to market & sell these seasonings & spices products. Online stores have emerged as one of the most favourable sales channels in the seasonings & spices products market since it is easily accessible to a large consumer base around the globe.

Segmentation

By Product

Herbs

Rosemary

Fennel

Garlic

Mint

Parsley

Oregano

Others

Salt & Salt substitutes

Spices

Pepper

Ginger

Cinnamon

Cumin

Turmeric

Cardamom

Coriander

Cloves

Others

By Application

Bakery and Confectionery

Soup

Meat and Seafood

Sauce, Salad, and Dressing

Savoury Snack

Other Applications

By Distribution Channel

Online Channels

Offline Channels

By Geography

North America (U.S. & Canada)

Europe (Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Indonesia, Taiwan, Australia, New Zealand and Rest of Asia Pacific)

Latin America (Brazil, Mexico, Argentina and Rest of Latin America)

Middle East & Africa (GCC, North Africa, South Africa and Rest of Middle East & Africa)

Competitive Landscape

The report profiles various major market players such as

-MDH Spices

-Nestle S.A

-The Kraft Heinz Company

-McCormick & Company Inc.

-Everest Spices

-DS Group

-Unilever

-Biova Gmbh

-Olam International

-Other Major & Niche Players

Access Complete Seasonings and Spices Market Report@https://www.fastmr.com/report/79/seasonings-and-spices-market

About Us:

FAST.MR is a global market research and business-consulting organization that aims to provide a deep market insight to our clients, which helps them in better decision making in the dynamic environment. We have a team of highly qualified personnel that studies the market in depth to provide our clients with better strategies to stand out in the market.

Contact Us:

Jason Lee

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email:[emailprotected]

Website:www.fastmr.com

For More Industry report Visit on Given Link https://www.fastmr.com/industry/1/food-beverages

Go here to read the rest:
Pharmaceutical and Biotechnology Market 2030 Is Booming Across the Globe Explored in Latest Research with Top Key Players. - Melanian News

Ferric Sulphate and Polyferric Sulphate market research study in brief

The business intelligence study for the Ferric Sulphate and Polyferric Sulphate market provides an extensive synopsis of essential aspects involving the product classification, important definitions, and other industry-specific parameters. The report also covers the key factors associated with the current events such as alliances, mergers & acquisitions, and new product launches.

Additionally, the Ferric Sulphate and Polyferric Sulphate market study puts forth a rigid basis for collecting a cluster of insights that potential customers can use to enhance their revenues and reduce costs. The illustration of data on Ferric Sulphate and Polyferric Sulphate market segmentation by type, application, and geography offers a critical viewpoint of, what manufacturers are eyeing for the stipulated timeframe, 2019 2026.

This article will help the Ferric Sulphate and Polyferric Sulphate vendors understand the volume expansion outlook with impacting trends.

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=73649

All of the segments covered in the research study are examined on the basis of BPS, market share, revenue, and other crucial factors. Our business study presents how various segments are adding to the growth of the global Ferric Sulphate and Polyferric Sulphate market. It also offers information on key trends with regards to the segments studied in the report. This supports market players to focus on promising regions of the global Ferric Sulphate and Polyferric Sulphate market. The research study also delivers independent analysis on the segments as per absolute dollar opportunity.

Drivers and Restraints

The global ferric sulphate and polyferric sulphate market is witnessing a growing trend towards removing sludge in industrial wastewater. It is estimated that the 40% sludge produced globally originates in industrial wastewaters. Additionally, industrialisation is on the rise across the world. Moreover, in many emerging countries, due to the major constraints on space and clean water issues, the use of ferric sulphate is likely to gain more attention. The rising industries across middle east and Asia Pacific are likely to drive growth of the ferric sulphate and polyferric sulphate market.

The rising standards of sewage slush are also expected to drive growth. Slush has been categorised as a potentially harmful chemical in many countries due to its toxicity to all life forms alike. The continuous production, and difficulty of changing production methods, and growing awareness about depleting clean water reservoirs are likely to drive growth of the ferric sulphate and polyferric sulphate market.

Looking for Regional Analysis or Competitive Landscape in Ferric Sulphate and Polyferric Sulphate Market, ask for a customized report

Global Ferric Sulphate and Polyferric Sulphate Market: Geographical Analysis

The global ferric sulphate and polyferric sulphate market is expected to witness highest growth in North America region. The growing demand for dentistry, the expanding insurance coverage, and the numerous opportunities on the horizon in waste water and dentistry are expected to drive growth. Additionally, the global ferric sulphate and polyferric sulphate market is also expected to witness robust growth in Asia Pacific. The large population in the region, growing opportunities, and rising household income are expected to drive significant growth for the ferric sulphate and polyferric sulphate market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=73649

The research attempts to answer many queries such as:

Why Choose Transparency Market Research?

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=73649

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The companys exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMRs experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY 12207United StatesTel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Email: [emailprotected]Website: http://www.transparencymarketresearch.com

Read more:
Biotechnology Market Strategic Analysis by Top Companies, Region, Applications, Growth Factors, and Future Prospects and forecast up to 2025 - Fusion...

Published January 22, 2020, 8:24 AM

By Charissa Luci-Atienza

The House Committee on Science and Technology has approved a bill seeking to eliminate the regulatory complications hampering the commercial release of biotechnology products.

Bohol Rep. Erico Aristotle Aumentado (FACEBOOK / FILE PHOTO / MANILA BULLETIN)

The House panel, chaired by Bohol Rep. Erico Aristotle Aumentado, passed House Bill No. 3372, the proposed Modern Biotechnology Act, principally authored by AAMBIS-OWA Party-list Rep. Sharon Garin.

We already approved the bill with minor amendments. It aims to promote safe and responsible use of biotechnology, he told the Manila Bulletin in a text message.

The bill was passed on Tuesday or more than a month after the Department of Agriculture-Bureau of Plant Industry (DA-BPI) affirmed the safety of GR2E Golden Rice for direct use as food and feed, or for processing (FFP). A bio-safety permit was issued to the Philippine Rice Research Institute (PhilRice) and International Rice Research Institute (IRRI) for GR2E Golden Rice.

Aumentado said the bill will be referred to the House Committee on Appropriations, chaired by Davao City Rep. Isidro Ungab and House Committee on Ways and Means, chaired by Albay Rep. Joey Salceda for their scrutiny.

Then, after the two panels pass the bill, we will have our committee report and the bill will be reported out to the plenary for its approval, he said.

Garin, main proponent of bio-fortification since the 17th Congress, earlier called on the House leadership to pass her bill.

We are trying to dispel the notion that commercially-produced bio-fortified goods are potentially dangerous, she said.

It is time that safe and responsible use of biotechnology be included in the Philippine toolkit to meet national development goals, she added.

Garin noted the National Economic and Development Authority (NEDA) recognizes agricultural biotechnology as a priority sector and has a direct impact on AmBisyon Natin 2040.

Biotechnology will increase yields and better products, leading to more income for farmers, she said.

Citing 2015 statistics, Garin said the average poverty incidence in the Philippines is about 21.6 percent and is highest among farmers at 34.4 percent.

She sought the passage of House Bill No. 3372, the proposed Modern Biotechnology Act, that calls for the creation of the Biotechnology Authority of the Philippines (BioAP) to promote safe and responsible use of biotechnology in the country.

In her bills explanatory note, Garin said HB 3372 seeks to expedite the regulatory decision-making process in biotechnology to help ensure the health and well-being of Filipinos, promote competitiveness, help reduce hunger and poverty, and help mitigate the effects of climate change.

She sought the revision of the current regulatory regime to enable the Philippines to benefit from products of modern biotechnology without delay, believing that that it is still based on outdated knowledge and assumptions.

Right now, it takes 65 months or more to complete all requirements for the commercial release of modern biotechnology products. The cumbersome regulations can no longer be justified for they effectively discriminate against local public biotech research institutions which have limited resources to comply with the existing regulations, Garin, chairman of the House Committee on Economic Affairs, said.

Aside from increasing yields and better products that would lead to more income for countrys farmers, Garin said biotechnology will provide climate and weather resistant crops that will mitigate the effects of natural disasters.

Since the 1980s, modern biotechnology has developed many useful products. These include insulin and corn that are resistant to borers and to a specific herbicide. These GMO corn plants have helped keep livestock and poultry affordable, and improved the profitability of 406,000 small resource poor Filipino farmers, Garin said.

HB 3372 tasks the BioAP to provide leadership in biotechnology industry development and rationalize the regulation of modern biotechnology. The proposed Biotechnology Authority shall also provide sustained funding for modern technology programs in agriculture, agroforestry, food processing, health, and manufacturing high value products for local and international markets.

The BioAP, under the bill, shall be attached to function as an agency of the DOST.

The bill calls for the abolition of the National Committee on Biosafety of the Philippines (NCBP) and other modern biotech regulatory bodies, but their functions shall be absorbed by the BioAP.

Sitting as members of the BioAP are the DOST Secretary or a designated Undersecretary, four members to be recommended by the National Academy of Science and Technology of the Philippines (NASTPhil), and two members to be recommended by the Philippine Chamber of Commerce and Industry (PCCI).

The BioAP shall have a Secretariat headed by an Executive Director to be appointed by the President of the Philippines upon the recommendation of the DOST Secretary.

Garin said under her bill, the BioAP shall ensure that the government formulates and strictly implements science-based bio-safety guidelines and regulations.

HB 3372 provides that the following acts shall be prohibited and penalized: unauthorized destruction of biotech crops, whether the crops are used for experimental objectives or for production; sale or distribution of fake genetically modified organism (GMO) seeds; and any other acts that are inimical to the safe and responsible use of modern biotechnology and are violative of the regulations set by the BioAP.

The bill provides that if violation is committed by an individual, he or she shall be penalized with two years of imprisonment and/or fine amounting to P500,000.

If the violator is an institution or organization, a P10-million fine and/or suspension of privilege to operate within the Philippines shall be imposed.

Garins bill also provides that any donation, contribution, bequest, subsidy, or financial aid to the BioAP or any Department, state university and college (SUC), or research center in support of modern biotechnology shall constitute allowable deductions from taxable income of the donor, and shall be exempt from donors tax.

An initial funding of P500 million shall be allotted for the operations of the BioAP and the needed appropriations for the full implementation of the proposed Act shall be included in the annual General Appropriations Act, the measure provides.

Within six months following the effectivity of the proposed Act, the DOST Secretary and the BioAP Executive Director shall activate the BioAP and it is expected that within three months, the BioAP members will promulgate the implementing rules and regulations of the proposed Act.

Go here to read the rest:
House bill seeks to eliminate regulations that hamper commercial release of biotech products - Manila Bulletin

We welcome guest writers to all of our Todayville platforms. Heres a submission from Emily Folk. Emily is passionate about agricultural sustainability and more of her work can be found on her site,Conservation Folks. In this story, Emily Folk explains the USMCA Impact on Agriculture.

The United States Mexico Canada Agreement (USMCA) has been in the news a lot lately. The leaders of the respective nations signed the trade agreement on November 30, 2019, and ratification is pending. You can think of the USMCA as an updated version of the North American Free Trade Agreement (NAFTA).

U.S. President Donald Trump vowed to renegotiate NAFTA after publicly speaking unfavourably about it. The USMCA is the result of that vow. The agreement spans several areas, such as the origin of automobile parts and new labor laws in Mexico that make it easier for workers to unionize. The USMCA also has a sunset clause that makes its terms expire after 16 years. Plus, every six years, the leaders of the countries involved must agree on whether to extend the deal.

Some agriculture-specific stipulations also exist within the USMCA. Additionally, the agreement notably mentions biotechnology. Heres a closer look at how the USMCA might change these two industries.

One of the key points often mentioned about the USMCA is that parties expect the agreement to cause a $2 billion increase in U.S. agriculture exports, triggering a $65 billion rise in U.S. gross domestic product (GDP). Canada and Mexico are currently the top two exporting markets for American farmers, supporting more than 325,000 American jobs. In 2018, the food and agricultural exports destined for Canada and Mexico totaled more than $39.7 billion.

The USMCA also opens exporting opportunities that did not exist before. Now, U.S. dairy farmers will have expanded access to send products such as fluid and powdered milk, cheese and cream to Canadian parties. There will also no longer be U.S. tariffs on whey and margarine. This change is notable, considering the Canadian dairy market produced roughly 17% of the United States annual output over the past three years.

In exchange, Canada will give the United States new access to chicken and eggs, plus increased access to turkey. Plus, all other agriculture products traded between the U.S. and Mexico will be under a zero-tariff model.

Another improvement associated with the USMCA is that it looks at agricultural technology more broadly than other trade agreements have.

For example, the Trans-Pacific Partnership a proposed trade agreement between 12 nations only addressed biotechnology regarding recombinant DNA (rDNA). That process involves joining the molecules from two different species, then inserting the product into a host to create new genetic combinations. Instead, the USMCA opens possibilities for all kinds of agricultural technology, including gene editing. Moving ahead with biotechnology could be crucial for addressing pressing matters that affect agriculture, such as water scarcity.

Approximately 700 million people suffer from water scarcity, and that number could double by 2025. Also, the agriculture industry is the greatest user of water. Things must change both to address the growing water scarcity problem and to give farmers more options for growing things without using so much water.

Biotechnology has already helped, and it seems highly likely to continue spurring progress. In one example, scientists altered the expression of one gene common to all plants. This change led to a 25% increase in the plants water-use efficiency without adversely impacting yield or photosynthesis.

As part of the USMCA, Mexico, Canada and the United States agreed to improve information sharing and cooperation about biotechnology matters related to trade. That change could speed new developments, resulting in positive outcomes for all involved groups and the world at large.

A grading system for agricultural products defines trading procedures. For example, commercial buyers of a product grown in another country refer to the grading standards to set expectations about a products quality. The USMCA specifies that Canada will evaluate U.S. imported wheat and assign it a grade no less favourable than it would give Canadian-grown wheat.

Canada will also no longer require country of origin statements associated with inspection certificates or quality grades. The United States and Canada will discuss issues related to seed regulations under the USMCA, too.

Concerning Mexico and the United States, the two countries agreed to non-discriminatory grading standards and services. Moreover, a dialogue will begin between the two countries to flesh out the details for quality standards and grading regarding trade.

Its too early to say what the real-life effects will be of the changes outlined here. But, the commitments laid out within the USMCA seem like theyll represent clear improvements for agriculture professionals, as well as everyone who benefits from their goods.

Im Emily Folk, and I grew up in a small town in Pennsylvania. Growing up I had a love of animals, and after countless marathons of watching Animal Planet documentaries, I developed a passion for ecology and conservation. You can read more of my work by clicking this link: Conservation Folks.

Extreme Weather Patterns Causing State of Agricultural Emergency in Canada

See original here:
What the USMCA Might Mean for Agriculture and Biotechnology? - Todayville.com

I spend my time focused on leveraging biotechnology for the public good, and Im ecstatic about what well see in the coming years. Biotechnology is advancing at an unprecedented rate, and engineered biology, commonly referred to as synthetic biology (SynBio), is taking the world by storm. The past 12 months have seen a major focus on the bioeconomy, the economy based on biology and biotechnology. It promises to be integral to the next decade of growth and opportunity. Its hard to imagine that artificial intelligence has only been in resurgence since 2012 less than ten years. But as AI impacts the digital world, biotechnology impacts the physical world, and over the next decade, well see innovations that rival, or even outpace, AI.

If youre not well versed in biotechnology, it helps to understand the context were in. For thousands of years, weve had physical solutions to our problems. I have a heavy rock that needs to get from point A to point B, so I push it, pull it, or roll it. Then, during the industrial revolution, we developed industrial synthetic chemistry.For the last 100 to 150 years, we have combined physical and chemical technologies to accelerate the economy and the quality of life for people around the world.

Biotechnology adds an entirely new dimension of technology development in the bioeconomy

Now were in a new industrial revolution, bringing the bioeconomy to the forefront of technology and economic growth where were combining biotechnology with chemical and physical technologies to revolutionize the world.

Were combining biotechnology with chemical and physical technologies to revolutionize the world.

The bioeconomy is not a new concept. The U.S. has a robust bioeconomy in healthcare and agriculture and is a global leader in emerging biotechnologies. Its these emerging applications in engineered biology, however, that will drive the next wave of growth in the bioeconomy over the next decade. Just in 2019, weve seen scientists and engineers createnew therapies to incurable infectionsandways to make plants grow in soil that should be too salty. In recent years, the private sector and the government have partnered toadvance regenerative manufacturingandbiopharmaceutical development.

MIT scientists have figured out how to make plants grow in soil that should be too salty Fast Company

Innovations like these in the bioeconomy will increasingly be driven by our ability toleverage synthetic biology and other forms of engineered biology to change the paradigmof how we think about the life sciences.

While biotechnology and bioeconomy have enjoyed major growth over the past decade, in the last 12 months, the bioeconomy has become a central topic in academia, industry, and government. Recognizing the strategic advantage that leadership in biotechnology represents, 2019 saw the launch of theU.S. Promote and Protect the Bioeconomy initiativeas well as theDepartment of Defense establishing biotechnology as an enterprise modernization priority(BIO).

Biotech experts gather at the White House for Summit on Americas Bioeconomy GeekWire

Just in the past month, weve seen theEngineering Biology Research and Development Act of 2019 passed in the House and moved into the Senate for consideration.The DoD released a notice of intent to stand up a synthetic biology manufacturing innovation institute, commonly referred to as SynBio MII. The SynBio MII, like the two partner institutes already running, ARMI and NIIMBL, will accelerate the U.S. biomanufacturing industry in support of the bioeconomy.

Its the combination of a strong private sector, and federal government funding for research and development in this sector, that will drive the next decade of bioeconomy growth.

As exciting as new technology is, these advances rarely come without ethical and societal implications to misuse. In the last year, weve seen the overstep of biotechnology use with the Chinese and Russian application of human genome editing despite an international call for a moratorium on human genome editing. In addition, in the past year, the New York Times has reported extensively on Chinas misuse of genetic information and artificial intelligence to target minority populations. And at the end of the decade, the Department of Defense in December 2019 warned its service members against using at-home DNA kits.

As we stand on the edge of the next decade, two things have become clear. First, just as graphical processing units revolutionized our ability to do AI at-scale, the next decade will see unprecedented advances in biomanufacturing and our ability to produce new products at-scale in a global market. We will advance in our ability to manufacture and process large quantities of new products in faster and faster development cycles.

The second is that we need the U.S. to go all-in on biotechnology. There is no doubt our competitors see biotechnology as the future of global leadership. Chinas Made in China 2025 has put biotechnology at the heart of the initiative. If we are to have a globally leading bioeconomy, then we need everyone on board.

We need policymakers to pass legislation to bolster the bioeconomy and incentivize the growth of companies in the industry. This means we need new policies in economics, education, and workforce development. We need industry leaders to recognize this is no longer a technology just for watching, and the future of your company depends on your ability to adapt and capitalize on the future bioeconomy. We need scientists and engineers to bring hard technical skills to the field and finish the job of making biology a true engineering discipline. We need influencers, celebrities, and those in the spotlight to voice your support in revolutionizing the world. But most importantly, we need the consumer, thats you and me, to vote with our dollars and show that biotechnology is not just an interesting advance in technology, but mandatory to our future and our vitality.

The views expressed here are of Alexanders own and do not represent the official views of the Department of Defense or the U.S. government.

Originally published on https://alexandertitus.com/2019/12/30/biotechnology-2020-and-the-decade-of-the-bioeconomy/

The rest is here:
Biotech 2020 and the decade of the bioeconomy - SynBioBeta

Puma Biotechnology, Inc. [PBYI] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $9.96 after PBYI shares went up by 2.36% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $9.73.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Thu 27 Feb (In 37 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total Capital is 81.57, while its Total Debt

What about valuation? This companys Enterprise Value to EBITDA is -3.57. The Enterprise Value to Sales for this firm is now 1.11, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 36.62M shares outstanding, amounting to a total market cap of $356.31M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -77.31% from its 52-week high, and it has moved up 59.11% from its 52-week low.

This stocks Beta value is currently 1.73, which indicates that it is 10.35% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 61.95. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Original post:
Puma Biotechnology, Inc. [PBYI] moving up 2.36% What are the long-term prospects? - The Dwinnex